![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 05, 2014 6:35:58 AM
- Expect Sativex revenues to return to growth in 2014
- Robust pipeline of cannabinoid products
AIM-listed pharmaceutical company GW Pharmaceuticals said losses for the first quarter of 2014 widened as revenue improved.
The biopharmaceutical firm, known for its multiple sclerosis treatment Sativex, said pre-tax losses widened to $3.5m for the three months to December 31st compared to a loss of $2.4m a year earlier.
Total revenue for the period rose to £7.5m compared to £5.2m before.
Chief Executive Officer Justin Gover said: "In addition to our orphan epilepsy programme, as we move through 2014, we expect a significant amount of milestones, including Phase 3 cancer pain data for Sativex as well as important clinical progress across our robust pipeline of cannabinoid product candidates."
The group, which last year received regulatory approval in Switzerland for its treatment of spasticity due to multiple sclerosis, said it continues to expect Sativex revenues to return to growth in 2014. Sativex is approved for use in 25 countries.
Furthermore, it said upon the first patient being randomised into the planned US Phase 3 MS spasticity trials, it expects to receive a $5m milestone payment from pharmaceutical company Otsuka.
Cash and cash equivalents as at December 31st of £35.3m compared to £38.1m as at September 30th.
sharecast.com/news/gw-pharmaceuticals-operating-losses-widen/21461332.html
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM